Literature DB >> 9564833

Effect of 17beta-estradiol on somatostatin receptor expression and inhibitory effects on growth hormone and prolactin release in rat pituitary cell cultures.

D Djordjijevic1, J Zhang, M Priam, C Viollet, D Gourdji, C Kordon, J Epelbaum.   

Abstract

In the present study, we tested whether 17beta-estradiol (E2)-induced PRL sensitivity to somatostatin-14 (SRIF) involves selective up-regulation of discrete somatostatin receptor subtypes (ssts) in primary cultures of female rat pituitary cells. The efficacy of the endogenous peptide SRIF to inhibit GH and PRL secretion and cAMP accumulation was compared with those of octreotide (OCT), BIM-23052, BIM-23056, and BIM-23268, which have been reported to be relatively selective for rat sst2, sst3, and sst5. Experiments were performed in steroid-depleted media supplemented or not with 1 nM E2 for 96 h. SRIF, OCT, and BIM-23052 inhibited cAMP accumulation and GH release independently of E2. In contrast, all three agonists affected PRL release in E2-treated cultures only. Inhibition of cAMP accumulation by SRIF, OCT, and BIM-23052 was enhanced by exposure of cells to E2. The rank of potency of the agonists, OCT = SRIF > BIM-23052, was similar for GH and PRL inhibition. BIM-23268 was a weak agonist on GH, but not on PRL, secretion. BIM-23056 had no effect on the release of either hormone, but slightly inhibited cAMP formation in E2-treated cells. To verify whether SRIF receptor gene expression correlated with these observations, messenger RNA (mRNA) transcripts corresponding to the five ssts were measured by quantitative RT-PCR in the presence or absence of E2. Control cells expressed predominantly sst2 and sst3 transcripts; sst1 mRNA was present in moderate amounts, whereas sst4 and sst5 were only weakly expressed. E2 had a differential effect on distinct ssts; it increased mRNA concentrations corresponding to sst2 and sst3, and decreased that of sst1. These results indicate that sst2 and sst3 receptors are the major somatostatin receptors expressed in the female rat pituitary, and that both of them are positively regulated by estradiol. However, the capacity of lactotropes to respond to SRIF after exposure to E2 seems to depend more upon E2-induced up-regulation of the sst2 than of the sst3 receptor subtype.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9564833     DOI: 10.1210/endo.139.5.5990

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  14 in total

1.  Supra-physiological rhGH administration induces gender-related differences in the hypothalamus-pituitary-thyroid (HPT) axis in healthy individuals.

Authors:  P Sgrò; M Sansone; A Parisi; A Sartorio; A Sansone; F Romanelli; A Lenzi; L Di Luigi
Journal:  J Endocrinol Invest       Date:  2016-05-26       Impact factor: 4.256

Review 2.  The role of somatostatin analogs in Cushing's disease.

Authors:  Joost van der Hoek; Steven W J Lamberts; Leo J Hofland
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

Review 3.  Pituitary somatostatin receptor signaling.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Trends Endocrinol Metab       Date:  2010-02-09       Impact factor: 12.015

4.  Somatostatin and its receptors contribute in a tissue-specific manner to the sex-dependent metabolic (fed/fasting) control of growth hormone axis in mice.

Authors:  José Córdoba-Chacón; Manuel D Gahete; Justo P Castaño; Rhonda D Kineman; Raul M Luque
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-10-13       Impact factor: 4.310

5.  Aromatase and 5alpha-reductase inhibition during an exogenous testosterone clamp unveils selective sex steroid modulation of somatostatin and growth hormone secretagogue actions in healthy older men.

Authors:  Johannes D Veldhuis; Kristi L Mielke; Mihaela Cosma; Cacia Soares-Welch; Remberto Paulo; John M Miles; Cyril Y Bowers
Journal:  J Clin Endocrinol Metab       Date:  2008-12-16       Impact factor: 5.958

6.  Relative effects of estrogen, age, and visceral fat on pulsatile growth hormone secretion in healthy women.

Authors:  Johannes D Veldhuis; Susan B Hudson; Dana Erickson; Joy N Bailey; George Ann Reynolds; Cyril Y Bowers
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-05-26       Impact factor: 4.310

7.  Oestrogen-mediated regulation of somatostatin receptor expression in human breast cancer cell lines assessed with 99mTc-depreotide.

Authors:  B Van Den Bossche; E D'haeninck; F De Vos; R A Dierckx; S Van Belle; M Bracke; C Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-03-17       Impact factor: 9.236

8.  Differential regulation of somatostatin receptors 1 and 2 mRNA and protein expression by tamoxifen and estradiol in breast cancer cells.

Authors:  Juan A Rivera; Haydar Alturaihi; Ujendra Kumar
Journal:  J Carcinog       Date:  2005-07-14

Review 9.  Sex-steroid modulation of growth hormone (GH) secretory control: three-peptide ensemble regulation under dual feedback restraint by GH and IGF-I.

Authors:  Johannes D Veldhuis; Cyril Y Bowers
Journal:  Endocrine       Date:  2003-10       Impact factor: 3.925

10.  Expression of somatostatin receptor type-2 (sst2A) in immature porcine Leydig cells and a possible role in the local control of testosterone secretion.

Authors:  Joanna Fombonne; Zsolt Csaba; Ysander von Boxberg; Amandine Valayer; Catherine Rey; Mohamed Benahmed; Pascal Dournaud; Slavica Krantic
Journal:  Reprod Biol Endocrinol       Date:  2003-02-11       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.